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Summary. Peripheral blood lymphocytes of 46 recipients of 
lymphocyte-depleted bone marrow allografts were pheno- 
typically analysed over a period of 1 year. We investigated 
the repopulation of lymphocyte subpopulations and their 
relation with clinical parameters such as graft-versus-host 
disease (GVHD), graft-versus-leukaemia and cytomegalo­
virus (CMV) infection. The number of repopulated T cells 
varied strongly between the blood samples of the recipients. 
In 45% of the recipients the number of T cells recovered to or 
above normal levels within 3 months after bone marrow 
transplantation (BMT), whereas the other recipients 
remained below normal up to 1 year after BMT. In 
recipients with a high repopulation, the CD8+ T-cell subset 
contributed more to this high repopulation than the CD4+ T- 
cell subset. We showed that the majority of T cells of these 
recipients expressed the a(3 T-cell receptor, CD8, CD 5 7 and 
CDllb. HLA-DR was also highly expressed reflecting the 
activation stage of T cells in these recipients. BMT recipients 
with a high repopulation of CD8+ T cells showed a lower
incidence of leukaemic relapse than recipients with a low 
repopulation. The 3-year probability of relapse was 19% 
versus 64% (P =  0-03), respectively. The relative high 
number of CD8+ T cells at 3 months after BMT was not 
associated with the incidence of GVHD. In contrast, 
occurrence of CMV infection after BMT was significantly 
higher in these recipients. Our results indicate that CD8+ T 
cells, predominantly CD57+, of BMT recipients with an 
expansion of these cells represent an in vivo activated cell 
population. This CD8+ T-cell population may consist 
partially of cytotoxic cells with anti-leukaemic activity as 
suggested by a low relapse rate. The signal for the strong 
expansion of these CD8+CD57+ T cells after BMT is still 
unclear, but association with CMV infection suggests that 
viral antigens are involved.
Keywords: BMT, T-cell subsets, CDS 7, graft-versus- 
leukaemia, cytomegalovirus.
Allogeneic bone marrow transplantation (BMT) is an effective
treatment for with leukaemia that been
associated with graft-versus-leukaemia (GVL) activity (Hor­
owitz et al, 1990). Donor-derived cytotoxic effector cells 
appear to be involved in the elimination of residual leukaemic 
cells after BMT. Graft-versus-host disease (GVHD) is an adverse 
complication of allogeneic BMT, but is associated with this 
GVL activity (Horowitz et a l  1990). T-cell depletion of the graft 
reduces the incidence and severity of acute GVHD (De Witte et 
al, 1984), but unfortunately results in higher relapse rate 
(Horowitz et al, 1990). Cytomegalovirus (CMV) infection has
CorrevSpondence: Dr H. Dolstra, Division of Haematology, Department 
of Internal Medicine, University Hospital Nijmegen, Geert Grooteplein 
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also been suggested to be associated with decreased incidence 
of leukaemic relapse (Ringden, 1992). These data indicate 
that alloantigens and viral antigens may induce cell 
populations that mediate GVL activity after BMT.
CMV is frequently reactivated after allogeneic BMT and 
the onset of CMV infection is during the first 3 months. CMV 
profoundly stimulates CD8+ T cells which represent the 
majority of T cells in the blood of BMT recipients (Leroy et al, 
1986; Wursch et al, 1985; Yabe et al, 1990). Polyclonal 
stimulation of CD8+ cytotoxic T lymphocytes (CTL) occurs 
during viral infections (Nahill & Welsh, 1993). Reconstitu­
tion of CD8+ CMV-specific CTL response, during CMV 
infection after BMT, provides protection from the develop­
ment of CMV disease (Reusser et al, 1991). Most CD8+ T cells 
in BMT recipients express the CDS 7 antigen, whereas in
300 ©  1995 Blackwell Science Ltd
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healthy individuals CD8+CD57 T are a minor
lymphocyte subpopulation (Leroy el al, 1986; Wursch et al, 
1985; Yabe et al, .1990; Izquierdo et al, 1990; Fukuda et al, 
1994). This expression of the CD57 antigen on T cells 
appears to be a hallmark of CMV infection (Wursch et al, 
1985; Gratama et al, 1988; Autran et al, 1991; Labalette 
et al, 1994).
In this study we investigated reconstitution of peripheral 
blood lymphocyte (PBL) subpopulations in recipients of 
lymphocyte-depleted bone marrow allografts. We observed 
that the absolute number of T cells, of which the majority 
express TCRck/?, CD8 and CD57, returned to normal levels in 
approximately half of the recipients within 3 months after 
BMT. In contrast, T-cell numbers in the other recipients 
remained below normal for at least 1 year. The high 
repopulation of CDS1 T cells in BMT recipients was 
associated with a low relapse rate and with CMV infection. 
Therefore we suggest that the CD8+ T-cell population, 
predominantly CD57+, contains cytotoxic cells that obtain 
GVL activity during CMV infection after BMT.
MATERIALS AND METHODS
Patient characteristics. 46 patients (28 males and .18 
females) with a median age of 40 years (range 18-55) were 
transplanted for haematological diseases in the period July 
1990 to October 1993. Indications for transplantation were 
acute myeloid leukaemia (AML) in 17 patients (15 in first 
complete remission [CR1]), acute lymphoblastic leukaemia 
(ALL) in nine patients (eight in CR1), chronic myeloid 
leukaemia (CML) in 11 patients (all in first chronic phase 
[CPI]), non-Hodgkin's lymphoma (NHL) in four patients (all 
in CR1), multiple myeloma (MM) in three patients and 
severe aplastic anaemia (SAA), refractory anaemia (RA) in 
one patient each. All patients received an allogeneic bone 
marrow graft from an HLA-identical, mixed lymphocyte 
culture negative sibling. Donor marrow was depleted of 98% 
of lymphocytes by counterflow centrifugation using a four- 
chamber elutriator rotor in the Curamé 3000 centrifuge 
(Heraeus Separationstechnic, Ostenrode, Germany) (Plas et 
al, 1988). The absolute number of T cells infused ranged 
from 0-7 to 1-3 (median 0*9) x 10(’/kg body weight. Patients 
transplanted for haematological malignancies were condi­
tioned for BMT with cyclophosphamide (60 mg/kg body
M I I » W 6 and 5) fractionated total body
irradiation in two equal fractions of 4*5 Gy each on days —2 
and - 1 .  In 23 patients idarubicin (42 mg/m2) was added to 
the conditioning regimen by continuous intravenous (i.v.) 
infusion during 48 h. The patients transplanted for SAA 
were conditioned with total lymphoid irradiation to a total
dose of 12 Gy on days 9, 8 and - 7  followed by
cyclophosphamide (50 mg/kg body weight) on days - 5  to 
- 2 .  Cyclosporin A (CsA; 3 mg/kg body weight/d) was given 
by continuous i.v. infusion from days - 1  to 14, followed by
2 mg/kg body weight/d continuous i.v. on to day 21. From 
day 21 onward, CsA was given orally in. a dose of 6 mg/kg 
body weight/d to 12 weeks after BMT, followed by a gradual 
tapering off and discontinuation after 16 weeks post-grafting 
(Schattenberg et al, 1990). All patients received orally
acyclovir (4 x 400 mg/d) from days —9 to 60 as prophylaxis 
of herpes virus infection. CMV infection prophylaxis with 
hyperimmune globulin was not given.
CMV monitoring. IgG, IgA and IgM antibodies to CMV 
were tested prior to BMT in serum of both donor and 
recipient using an ELISA. An antibody titre of >10 was 
considered positive. The presence of CMV in urine samples 
was determined using a standard method. Briefly, fibroblast 
cell line HEL was grown to confluency in flat-bottom tubes
containing a Tubes with cells were inoculated
with urine specimen by centrifugation for 45m in at 37UC, 
After 48 h, cells were lixed with methanol for 20m in at 4°C 
and examined for detection of immediate-early antigen with
the MoAb NBA (Dupont, Germany) by
indirect immunofluorescence. The presence of CMV antigen 
in blood was determined using a standard method. Briefly, 
granulocytes were isolated from citrate-anticoagulated blood 
by dextran. Cells were collected and cytospin preparations 
(1-5 x 10s cells/eytospin) were made. Cytospin preparations 
were fixed with acetone for lOmin at room temperature 
(RT) and examined for detection of pp65 antigen with the 
MoAbs CMV-C10 and CMV-C11 (Biotest, Dreieich, Germany) 
by indirect immuno-alkaline phosphatase staining. CMV 
infection was defined by the presence of CMV antigen in 
blood and/or CMV in cultures of urine samples. CMV disease 
was defined by evidence of CMV in bronchoalveolar lavage 
fluid, in tissue sections of the liver or by gastrointestinal 
endoscopy plus evidence of CMV in biopsies associated with 
clinical signs and symptoms.
Blood sampling and haematological parameters. Peripheral 
blood samples were obtained from donors and patients at 
2 weeks before BMT and from patients at 1, 3, 6, 9 and 12 
months after BMT. The haematological parameters 
including leucocyte differential counts were
by a Tec 
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lysed in FACS lysing reagent (Becton Dickinson) at RT for 
lOmin. After lysis, cells were washed in phosphate-buffered 
saline and finally in 1% paraformaldehyde
solution. Cells were analysed on an Epics Elite flow cytometer 
(Coulter Corporation, Hialeah, Fla.). Indirect immunopheno- 
typing was performed as follows. PBL were suspended in PBS 
supplemented with 20% pooled human serum (PHS) and 
0-1% NaNj. Cell suspensions of 1 0 0 /¿I (106 cells) were 
incubated (20 min, 4°C) with the appropriate concentration 
of Mo Ab. Cells were washed in PBS supplemented with 0-5% 
bovine serum albumin and subsequently incubated (20 min, 
4DC) with FITC-conjugated F(ab')2 fragment goat-anti-mouse 
IgG (American Qualex International, La Mirada, Calif.) diluted 
in PBS supplemented with 20% PHS and 0• 1 % NaN3. After 
washing, the cells were incubated with 10% normal mouse 
serum in PBS supplemented with 20% PFIS and 0*1% NaN3 
for 10 min at 4°C to block free binding sites of the goat-anti- 
mouse IgG. Finally, cells were incubated with UCHT1-PE 
(CD3) for 20 min at 4°C. Cells were washed and analysed by 
flow cytometry (FCM).
Statistical analysis. Absolute numbers of lymphocyte 
subpopulations of BMT recipients and normal individuals 
were compared using the non-parametric Mann-Whitney U- 
test. Correlations between absolute numbers of lymphocyte 
subpopulations at different time periods after BMT were 
analysed with the Spearman’s rank test. Relapse and
survival analysis was performed using the Kaplan-Meier 
product-limit method. Actuarial curves were calculated for 
relapse, survival and leukaemia-free survival (LFS) and the 
effect of high repopulation of T cells on the curves was 
compared using the log-rank test. The Fisher’s exact test was 
used to assess differences in clinical parameters. For all tests 
P value <0-05 was considered significant.
RESULTS
Phenotypic analysis of lymphocytes after BMT  
PBL of BMT recipients were analysed by FCM at several time 
periods until 1 year postgrafting. Fig .1 shows the absolute 
number of repopulated lymphocyte subpopulations in 
comparison with lymphocyte numbers of normal 
individuals. The median number of both NK cells and T 
cells were below the normal range for at least 1 year. The 
median number of CD8+ T cells was also below normal at 1 
month, but increased to normal within 3 months. CD4+ T 
cells repopulated very slowly and the median number 
remained below normal during the whole follow-up period. 
Almost all CD4+ cells coexpressed CD45RO corresponding 
with a helper and memory phenotype (data not shown). The 
percentage of NK cells was higher than normal at 1 month 
after BMT, but by increasing numbers of T cells this returned 
gradually to normal during the subsequent months.
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Fig 1. Repopulation of lymphocyte subpopulations in peripheral blood from recipients of lymphocyte-depleted bone marrow 
Lymphocyte population was analysed by flow cytometry for T cells (CD3+), NK cells (CD3~CD56+), CD4+ T cells and CD8+ T cells. Data are 
represented as the absolute number of cells of indicated subpopulation with median number at each time period shown by thick bar. Shaded area 
represents the mean number of cells ±  SD of analysis of 20 normal controls. * P < 0001 , # P < 0 0 1 , $ P < 0 0 5  with respect to normal control,
by the Mann-Whitney U test. Closed circles represent recipients in group 1 (CD8+ T-cell number < 0 2 8  x 109/1 at 3 months) and open circles
represent group 2 (CD8+ T cell number >0-28 x 1.09/l at 3 months) at 3, 6 and 9 -1 2  months after BMT.
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As shown in Fig 1, the number of T cells varied strongly 
between the blood samples of BMT recipients. T-cell numbers 
of some patients increased towards normal values between 1 
and 3 months after BMT. Statistical analysis revealed that 
the number of circulating T cells was strongly correlated 
with the number of CD8+ T cells at 3 months after BMT 
(r =  0-99, P =  0-001). Although the number of CD4+ T cells 
was also significantly correlated with the number of T cells at
3 months after BMT (r =  0-62, P =  0-001), the CD8+ T-cell 
subset contributed more to the number of T cells than the 
CD4+ T-cell subset, as shown by the correlation coefficients.
The absolute number of T cells at 3 months after BMT was 
strongly correlated with coexpression of the CD 5 7 antigen 
on these cells (Fig 2; r — 0-70, P < 0-001). To determine 
coexpression of other antigens on T cells, PBL of five BMT 
recipients with a high repopulation of T cells were 
additionally characterized (Fig 3). The majority of these T 
cells expressed both CD8 and CD5 7 (68-88%). 90% of T cells 
expressed the a/3 T-cell receptor (87-98%). In all five 
patients studied, <30% of T cells expressed CD4. Further­
more, we studied the expression on these cells of EL-2 
receptor a-chain (CD25) and HLA-DR because both antigens 
are associated with T-cell activation. A small percentage of T 
cells expressed CD25 (1-16%), whereas HLA-DR was 
expressed on 48-76%  of T cells. CDllb which is frequently 
coexpressed with CD5 7 on lymphocytes after BMT (Yabe et al,
9T cells (x10 /I)
Fig 2. Regression analysis of absolute number of T cells versus 
percentage of these cells that express the CD 5 7 antigen.
expressed 88% of T cells. These data
show that in BMT recipients with a high repopulation of T 
cells the majority of these cells express TCRap, CD8, CD57, 
CDllb and HLA-DR.
Table I. Clinical data of patients transplanted in CR1/CP1 from group 1 with low numbers of CD8+ T 
cells and patients from group 2 with relatively high numbers of CD8+ T cells.
Group 1 Group 2 Statistics
No. of patients 21 17
Median age* 37 40 NS
Male/female 16/5 8/9 NS
Underlying disease
AML 8 (38%) 7 (41%) NS
' ALL 4 (19%) 4 (23%) NS
CML 8 (38%) 3 (18%) NS
NHL 1 (5%) 3 (18%) NS
Conditioning regimen with idarubicin 13 (62%) 9 (53%) NS
T cells x 106 /kg transplanted 0-9 ± 0-2 0-9 ±0-2 NS
Probability of relapsef (64%) (19%) 0-03
Probability of LFS (34%) (60%) NS
Probability of survival (61%) (63%) NS
Transplant-related mortality 2 (10%) 3 (18%) NS
Acute GVHD grade 2 4 (19%) 4 (23%) NS
Chronic GVHD
Limited 8 (38%) 4 (24%) NS
Extensive 1 (5%) 4 (24%) NS
CMV serology pre-BMT
Recipient negative/donor negative 16 (76%) 2 (12%) 0-001
Recipient negative/donor positive 1 (5%) 2 (12%) NS
Recipient positive/donor negative 3 (14%) 3 (17%) NS
Recipient positive/donor positive 1 (5%) 10 (59%) 0-001
CMV infection after BMT 2 (10%) 12 (71%) 0-001
Age at time of transplantation in years, 
f  Projected 3-year probability.
© 1995 Blackwell Science Ltd, British Journal of Haematology 90: 300-307
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TCR (xJ3 CD4 CD8 CD57 CD11b
Antigens expressed on T cells
CD25 HLA-Dr Fig 3. Coexpression of antigens on T c 
patients from group 2.
On the basis of the difference in repopulation of CD8+ T 
cells, patients were divided in two groups. The median 
number of CD8+ T cells at 3 months after BMT was 
0-28 x 109/1 (range 0-02-3-87 x 109/1). This value was 
chosen retrospectively as a cut-off point to divide the patients 
in two equally sized groups. The mean number of CD8+ 
T cells at 3 months after BMT in group 1 (24/46 patients) 
was strongly below normal CD8+ T-cell numbers 
(0-14 ±  0-08 x 109/1 and 0-42 ±  0-14 x 109/1, respec­
tively; P < 0-001; Fig 1, closed circles). The mean number 
of CD8+ T cells at 3 months after BMT in group 2 (22/46  
patients) was above normal levels (1-06 ±  0-92 x 199/1 and 
0-42 ± 0 -1 4  x 109/1, respectively; P < 0-001; Fig 1, open 
circles).
These data demonstrate that in 45% of the recipients the 
number of CD8+ T cells recovered above normal levels 
within 3 months after BMT, whereas the other recipients 
remained strongly below normal levels.
Relationship between repopulation of CD8+ T cells and clinical 
data
To determine the contribution of CD8+ T-cell repopulation to 
the clinical outcome, clinical data of both patient groups 
were evaluated (Table I). Patients with MM, SAA and RA as 
underlying disease and patients not in CR1 or CPI were not 
included in this evaluation. Both groups were not signifi­
cantly different with regard to age, sex, underlying disease, 
conditioning therapy and T cells/kg body weight trans­
planted. However, a significant difference could be found in 
the projected 3-year probability of relapse between patients 
transplanted in CR1/CP1 in groups 1 and 2, 64% versus 
19% (P =  0-03, Fig 4A). The probability of survival was not 
significantly different between the two groups (Table I). The 
projected 3-year probability of survival for group 1 was 61% 
and for group 2 63% (P =  0-64). No difference was found in 
transplant-related mortality (TRM) between groups 1 and 2, 
10% versus 18% (P =  0-40), respectively. However, a trend 
was observed towards a longer leukaemia-free survival (LFS) 
for recipients in group 2 with a projected 3-year probability 
of LFS of 60% versus 34% for group 1 (P =  0-15, Fig 4B).
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Fig 4. Probability of relapse (A) and LFS (B) in the two distinct 
patients groups. Group 1 represents recipients with a low number of 
CD8+ T cells at 3 months after BMT and group 2 represents recipients 
with a relative high number of CD8+ T cells at 3 months after BMT. 
Tick marks in the curves denote leukaemia-free survivors.
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The projected 3-year probability of relapse, survival and LFS 
for all patients studied was 43%, 62% and 46%, respectively.
No significant differences in acute and chronic GVHD were 
found between the two groups (Table I). A positive CMV 
serologic determination of both recipient and donor prior to 
BMT was more frequently detected in group 2 than in group 
1 (P =  0-001). Moreover, a negative CMV serologic 
determination of both recipient and donor prior to BMT 
was more frequently detected in group 1 than in group 2 
(P =  0-001). The incidence of CMV infection after BMT was 
significantly higher in group 2 (12/17) than in group 1 (2/ 
21, P < 0-001). The median time of onset of CMV infection 
was 9 weeks (range 5 -1 2  weeks). None of the patients 
studied developed CMV disease.
Although the probability of relapse and LFS for patients 
with CMV infection ( n =  14) versus patients without CMV 
infection (n =  24) showed differences, it was not statistically 
significant. The projected 3-year probability of relapse for 
patients with CMV infection was 23% and for patients 
without CMV infection 47% (P =0*40). The projected 3- 
year probability of LFS for patients with CMV infection was 
56% and for patients without CMV infection 45% 
(P =  0-92).
These data indicate that high repopulation of CD8+ T 
cells, predominantly CD 5 7+, is related with a low incidence 
of leukaemic relapse. Moreover, high repopulation of CD8+ T 
cells is correlated with the occurrence of CMV, suggesting 
that viral antigens are involved.
DISCUSSION
Donor-derived cytotoxic cells of recipients of bone marrow 
allografts appear to be involved in the elimination of residual 
leukaemic cells that survive the pretransplant conditioning 
regimen. Clinical data support such GVL activity by both 
GVHD-dependent and GVHD-independent effector mechan­
isms (Horowitz et al, 1990). We studied repopulation of PBL 
in recipients of lymphocyte-depleted bone marrow allografts 
to investigate the relation of recovery of lymphocyte subsets 
and GVL activity.
Between 1 and 3 months after BMT the number of T cells 
repopulated to or above normal levels in 45% of the BMT 
recipients studied. This high repopulation of T cells was the 
result of an increase of both CD4+ and CDS'1 T cells but the 
CDS 1 T-cell subset contributed more to the high repopula­
tion of T cells than the CD41 T-cell subset.
Expansion of CDS 1 T cells between 1 and 3 months after 
BMT was accompanied by coexpression of the CD 5 7 antigen 
on these cells. CD57 is a lineage-nonrestricted glycoprotein 
that normally is expressed on a subpopulation of NK cells 
and a minority of T cells. The function of this antigen 
recognized by CD 5 7 MoAbs is still unknown. Kruse et al 
(1984) have shown that a carbohydrate structure of neural 
cell adhesion molecule (NCAM) and myelin-associated 
glycoprotein (MAG) is recognized by CD57 MoAbs. Lallier 
et al (1992) have identified an al/31 integrin on avian 
neural crest cells that bears the CD5 7 epitope and is involved 
in adhesion to laminin. Therefore the CD 5 7 antigen 
expressed on lymphocytes after stimulation in certain
pathological conditions may be involved in adhesion. 
CD8+CD57+ T cells mediate in vitro IL-2- and anti-CD3- 
induced cytotoxicity (Philips & Lanier, 1986; Leroy et al, 
1990; Madariage et al, 1990). However, it has also been 
described that these cells inhibit cytotoxicity of allospecific 
CTL or NK cells as well as mitogen-induced B- and T-cell 
proliferation (Leroy etal, 1986; Autran etal, 1991).
HLA-DR was expressed on most T cells of BMT recipients 
with a high repopulation of these cells. This suggests that 
these cells has been activated in vivo. However, <15% of 
these cells expressed the IL-2 receptor a-chain (CD25). 
Expression of CDllb the a-subunit of integrin Mac-1 
(CDllb/CD18), also associated with lymphocyte activa­
tion, was found on 33-88% of these T cells. Normally 
CD1 lb  is only expressed on the surface of a small subset of T 
cells and on all neutrophils, eosinophils, monocytes, and 
most NK cells and plays a role in adhesion (Schleiffenbaum et 
al, 1989). McFarland et al (1992) found that CDllb is 
expressed on a subset of CD8+ T cells that include active 
virus-specific CTL. Therefore Mac-1 might be involved in 
cellular interactions resulting in activation and cytolytic 
activity of CD8+CD57+ T cells.
The increase of CD8+CD57+ T cells in BMT recipients 
seems to be the result of stimulation by alloantigens and/or 
viral antigens (Leroy et al, 1986; Wursch etal, 1985; Yabe et 
al, 1990; Izquierdo et al, 1990; Fukuda et al, 1994). It has 
been described that increased numbers of CDS+CD57+ T 
cells correlate with the incidence of GVHD (Yabe et al, 1990; 
Fukuda et al, 1994). In contrast to these investigators, we 
found that the increase of CD8+CD57+ T cells is not 
correlated with the incidence of GVHD, but our results 
confirm and extend the observation that the increase of 
CD8+CD57+ T cells is strongly correlated with a positive 
CMV serology of both recipient and donor prior to BMT 
(Wursch et al, 1985; Izquierdo et al, 1990). Moreover, 
occurrence of a CMV infection after BMT, defined by the 
presence of CMV antigen in blood and/or CMV in cultures of 
urine samples, was significantly higher in patients with 
increased numbers of CD8+CD57+ T cells. However, none of 
the BMT recipients in this study developed CMV disease 
although no prophylactic or therapeutic treatment was 
given with ganciclovir or foscarnet. CMV infection has also 
been associated with an increased risk of GVHD (Ringden 
1992), but the incidence of GVHD in this study was low due 
to lymphocyte depletion of the graft by counterflow 
centrifugation (De Witte et al, 1984; Schattenberg et al,
We observed a lower relapse rate in leukaemia patients 
transplanted in CR1 or CPI with a relatively high number of 
CD8+ T cells 3 months after BMT than in patients with a low 
number of CD8+ T cells (19% v 64%; P =  0-03). This 
observation suggests that an increase of CD8+ T cells after 
BMT associated with CMV infection prevents leukaemic 
relapse independent of GVHD. Ringdén et al (1988) and 
Lônnqvist et al (1986) showed that patients with a CMV 
infection after BMT had a reduced risk of recurrent 
leukaemia. Moreover, transplantation of bone marrow 
from CMV seropositive donors resulted in lower incidence 
of leukaemic relapse (Jacobsen et al, 1986). Therefore we
C) 1995 Blackwell Science Ltd, British Journal of Haematology 90: 300-307
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hypothesize that donor-derived CTL become activated during 
CMV infection which induces GVL activity. Prophylactic 
treatment with ganciclovir may lead to a delay in recovery 
of CMV-specific immunoresponse because of the absence of 
CMV infection (Li et al, 1994). This prophylactic treatment 
for CMV infection could increase the incidence of leukaemic 
relapse.
Viral infections appear to stimulate the generation of 
alloantigen-specific CTL coincidental with the generation of 
virus-specific CTL (Nahill & Welsh, 1993; Yang et al, 1989; 
Tomkinson et al, 1989). Nahill & Welsh (1993) reported that 
a high frequency of these CTL were cross-reactive for 
allogeneic and virus-infected syngeneic target cells. More­
over, CTL clones have been isolated specific for a HLA-B8 
restricted Epstein-Barr virus epitope and cross-reactive with
the alloantigen HLA-B44.02 (Burrows et al, 1994).
In conclusion, in this report we demonstrate that high 
repopulation of CD8+ T cells after lymphocyte-depleted 
allogeneic BMT is related with a lower relapse rate. Relation 
between CMV infection and high numbers of CD8+ T cells in 
BMT recipients suggests that CMV can be the signal for 
expansion of these cells. To elucidate the trigger for 
expansion of CD8+ T cells after BMT and the role of CD57, 
CDllb and HLA-DR antigens on these cells further studies 
are needed. Investigations whether donor-derived CTL show 
cross-reactivity against the recipient’s leukaemic cells upon 
stimulation during CMV infection and determination of the 
specificity of these cells are in progress.
ACKNOWLEDGMENTS
This work was supported in part by grants from the ‘Ank van 
Vlissingen Foundation’ and the ‘Maurits and Anna de Kock 
Foundation’.
REFERENCES
Autran, B., Leblond, V., Sadat-Sowti, B., Lefranc, E., Got, P., Sutton, 
L., Binet, J.L. & Debre, P. (1991) A soluble factor released by 
CD8+CD57+ lymphocytes from bone marrow transplanted 
patients inhibits cell-mediated cytoiysis. Blood, 77, 2237-2241 .
Burrows, S.R., Khanna, R., Burrows, J.M. & Moss, D.J. (.1994) An 
alloresponvse in humans is dominated by cytotoxic T lymphocytes 
(CTL) cross-reactive with a single Epstein-Barr virus epitope: 
implications for graft-versus-host disease. Journal of Experimental
, 179, 1155 -11 61 .
De Witte, T., Raymakers, R., Pias, A., Koekman, E., Wessels, f. & 
Haanen, C. (1984) Bone marrow repopulation capacity after 
transplantation of lymphocyte depleted allogeneic bone marrow 
using counterflow centrifugation. Transplantation, 37, 151-155 .
Fukuda, H., Nakamura, H., Tominaga, II., I-Iiraoka, A., Shibata, II. & 
Masaoka, T. (1994) Marked increase of CD8'S6F1+ and CD8+ 
CD57+ cells in patients with graft-versus-host disease after 
allogeneic bone marrow transplantation. Bone Marrow Transplan­
tation, 13, 1 8 1 -1 8 5 .
Gratama, J.W., Kluin-Nelemans. H.C., Langelaar, R.A., Den 
Ottolander, R.A., Stijnen, G.J., D’Amaro, J., Torensma, R. & 
Tanke, H.J. (1988) Flow cytometry and morphologic studies of 
HNK1+ (Leu7+) lymphocytes in relation to cytomegalovirus 
carrier status. Clinical and Experimental Immunology, 74, 1 9 0 -  
195.
Horowitz, M.M., Gale, R.P., Sondel, P.M., Goldman, J.M., Kersey, J., 
Kolb, H.J., Riram, A.A., Ringdén, 0„ Rozman, C„ Speck, B., Truitt, 
R.L., Zwaan, F.E. & Bortin, M.M. (1990) Graft-versus-leukemia 
reactions after bone marrow transplantation. Blood, 75, 555— 
562.
Izquierdo, M., Balboa, M.A., Ferândez-Ranada, J.M., Figuera, A., 
Torres, A., Iriondo, A. & Lôpez-Botet, M. (1990) Relation between 
the increase of circulating CD3+CD57+ lymphocytes and T cell 
dysfunction in recipients of bone marrow transplantation. Clinical 
and Experimental Immunology, 82, 145-150 .
Jacobsen, N., Andersen, I-I.K., Lcînnqvist, B., Skinkoj, P., Rijder, L.P., 
Platz, P., Jerne, D. & Faber, V., for the Copenhagen Bone Marrow 
Transplantation Group (.1986) Correlation between donor 
cytomegalovirus immunity and chronic graft-versus-host disease 
after allogeneic bone marrow transplantation. Scandinavian 
Journal of Haematology, 36, 4 9 9 -5 0 6 .
Kruse, J., Mallhammer, R., Wemecke, H., Faissner, A., Sommer, I., 
Gorldis, C. & Schachner, M. (1984) Neural cell adhesion 
molecules and myelin-associated glycoprotein share a common 
carbohydrate moiety recognised by monoclonal antibodies L2 and 
HNK-1. Nature, 311, 153-155.
Labalette, M., Salez, F., Pruvot, F.R., Noel, C. & Dessaint, J.P. (1994) 
CD8 lymphocytosis in primary cytomegalovirus (CMV) infection 
of allograft recipients: expansion of uncommon CD8+CD57~ 
subset and the progressive replacement by CD8+CD57+ T cells. 
Clinical and Experimental Immunology, 95, 465 -471 .
Lallier, T. & Bronner-Fraser, M. (1992) a l / i l  integrin on neural 
crest cells recognizes some laminin substrata in a Ca2+- 
independent manner. Journal of Cell Biology, 119, 1335-1345.
Leroy, E., Calvo, C.F., Divine, M., Gourdin, M.F., Baujean, F., Ben 
Aribia, M.H., Mishal, Z., Vernant, J.P., Farcet, J.P. & Senik, A. 
(1986) Persistence of T8+/HNK-1+ suppressor lymphocytes in 
the blood of long-term surviving patients after allogeneic bone 
marrow transplantation. Journal of Immunology, 137, 2 ISO- 
2189.
Leroy, E., Madariaga, L., Aribia, M.B., Mishal, Z., Theodorou, I., 
Rochant, H., Vernant, J.P. & Senik, A. (1990) Abnormally 
expanded CD8+/Leu-7+ lymphocytes persisting in long-term bone
marrow transplanted patients are pre-cytotoxic T-
lymphocytes. Experimental Hematology, 18, 770-774.
Li, C.L., Greenberg, P.D., Gilbert, M.J., Goodrich, J.M. & Riddell, S.R. 
(1994) Recovery of HLA-restricted cytomegalovirus (CMV)- 
specific T-cell responses after allogeneic bone marrow trans­
plant: correlation with CMV disease and effect of ganciclovir 
prophylaxis. Blood, 83, 1971-1979 .
Lônnqvist, B., Ringdén, 0., Ljungman, P., Wahren, B. & Gahrton, G. 
(1986) Reduced risk of recurrent leukaemia in bone marrow 
transplant recipients after cytomegalovirus infection. British 
Journal of Haematology, 63, 671-679 .
Madariage, L., Leroy, E., Moiré, N„ Rouleau, M., Mishal, Z., Rochant, 
II,, Vernant, J.P., Charpentier, B., Ben Aribia, M. & Senik, A. 
(1990) Induction of cytolytic function in resting peripheral blood 
CD8+/Leu-7+ T cells through IL2/p75 IL2-receptor interaction: a 
study in the allogeneic human bone marrow transplantation 
model. Cellular Immunology, 130, 291-302 .
McFarland, H.I., Nahill, S.R., Maciaszek, J.W. & Welsh, R.M. (1992) 
CD1 lb (Mac-1 ): a marker for CD81 cytotoxic T cell activation and 
memory in virus infection. Journal of Immunology, 149, 1326-
1333.
Nahill, S.R. & Welsh, R.M. (1993) High frequency of cross-reactive 
cytotoxic T lymphocytes elicited during the virus-induced 
polyclonal cytotoxic T lymphocyte response. Journal of Experi­
mental Medicine, 177, 317-327 .
Philips, J.H. & Lanier, L.C. (1986) Lectin-dependent and anti-CD3
©  1995 Blackwell Science Ltd, British Journal of Haematology 90: 300-307
T-cell Expansion after BMT 307
induced cytotoxicity are preferentially mediated by peripheral 
blood cytotoxic T lymphocytes expressing Leu-7 antigen. Journal 
of Immunology, 1 36, 1579-1585 .
Plas, A., De Witte, T., Wessels, J. & Haanen, C. (1988) A new 
multichamber eounterflow centrifugation rotor with 
separation capacity and versatile potentials. Experimental 
Hematology, 16, 355-359.
Reusser, P.. Ridell. S.R., Meyers, J.D. & Greenberg, P.D. (1991) 
Cytotoxic T-lymphocyte response to cytomegalovirus after human 
allogeneic bone marrow transplantation: pattern of recovery and 
correlation with cytomegalovirus infection and disease. Blood, 78, 
1 3 7 3 -1 3 8 0 .
Ringdén, ()., Sundberg, B. & Lônnqvist, B. (1988) Allogeneic bone 
marrow transplantation for leukemia: factors of importance for 
long-term survival and relapse. Bone Marrow Transplantation, 3, 
2 8 1 -2 9 0 .
Ringdén, 0. (1992) Correlation of pretransplant viral serology and 
complications of bone marrow transplantation. Annals of
if, 64, 143—147.
Schattenberg, A., De Witte, T., Preijers, I’., Raemaekers, J., Muus, P., 
Van Der Lely, N., Boezeman, J., Wessels, J., Van Dijk, B., 
Hoogenhout, J. & Haanen, C. (1990) Allogeneic bone marrow 
transplantation for leukemia with marrow grafts depleted of
lymphocytes by eounterflow centrifugation. Blood, 75, 1 3 5 6 -  
1363.
Schleiffenbaum, B., Moser, R., Patarroyo, M. & Fehr, J. (1989) The 
cell surface glycoprotein Mac-1 (CDllb/CD18) mediates neutro­
phil adhesion and modulates degranulation independently of its 
quantitative cell surface expression. Journal of Immunology, 142, 
3537-3545 .
Tomkinson, B.Ë., Marlarz, R. & Sullivan, J.C, (1989) Characteriza­
tion of the T-cell-mediated cellular cytotoxicity during acute 
Infectious mononucleosis. Journal of Immunology, 143, 660-670 .
Wursch, A.M., Gratama, J.W., •p, J.M., rf  V* ! *
Gratwohl, A., Speck, B„ Jansen, J., D'Amoro, J., The, T.II. & De 
Gast, G.C. (1985) The effect of cytomegalovirus infection on T
lymphocytes after bone marrow transplantation.
Clinical and Experimental Immunology, 62, 278-287 .
Yabe, H., Yabe, M., Kato, S., Klmura, M. & Iwaki, K. (1990)
" ■'+CD 11+, CD8 * CD 11 and CD8 1 Leu 7+■'«Jas«
cells in patients with chronic graft-versus-host disease after 
allogeneic bone marrow transplantation, Bone Marrow Transplan­
tation, 5, 295-300 .
Yang, H„ Dundon, P.L., Nahill, S.R. & Welsh, R.M. (1989) Virus- 
induced polyclonal cytotoxic T lymphocyte stimulation, journal of
, 142, 1710-1718.
C‘> 1995 Blackwell Science Ltd, British Journal of Haematology 90: 300-307
